CRRT is a slow and gentle dialysis procedure that continuously eliminates extra fluids and waste products from the blood, much like the kidneys do in healthy people.
Utilization of CRRT for the Treatment of Critically ill Patients with Acute Kidney Injury (AKI) Fuels Demand in Continuous Renal Replacement Therapy (CRRT) Market
Acute Kidney Injury (AKI) is a worldwide issue that is common in critically unwell patients. AKI affects an estimated 13.3 million people worldwide each year, with poor countries accounting for 85% of those affected. CRRT for critically sick patients with AKI aims to maintain fluid, electrolyte, acid-base, and solute balance, assist renal recovery, and allow other supportive therapies to continue without complication or constraint.
Advantages Attributed to CRRT Drives the Continuous Renal Replacement Therapy (CRRT) Market Growth
Critically sick patients with AKI who are receiving Renal Replacement Therapy (RRT) frequently have periods of hemodynamic instability. When compared to other intermittent treatments, such as intermittent hemodialysis (IHD) and sustained low-efficiency dialysis, CRRT may have a better hemodynamic profile. Among the advantages of CRRT over conventional RRT is the ability to prevent changes in intracerebral water. In patients at risk of cerebral edoema, CRRT is also thought to be safer than IHD.
Rising Awareness Regarding Kidney Health & Prevention Program Propells the Renal Replacement Therapy (CRRT) Market
Currently, organisations such as the National Kidney Foundation (NKF), The National Kidney Disease Education Programme (NKDEP), and local governments around the world run a large number of kidney health and prevention programmes to raise awareness about evidence-based interventions to improve understanding, detection, and management of kidney disease. For instance,
Â§ In September 2022, Fresenius Medical Care, announced they have signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, this collaboration is to join efforts in raising awareness about kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia
The global healthcare systems have faced significant challenges due to the COVID-19 pandemic. Among the patients hospitalized with COVID-19, a considerable proportion, ranging from 15% to 30%, exhibited signs of kidney failure and required Continuous Renal Replacement Therapy (CRRT). In these instances, CRRT acted as a life-sustaining and life-saving therapy.
The high cost of the CRRT procedures and the risk & complications associated with the CRRT such as catheter-related complications, blood loss, infection or access failure, fluctuations in salt balance, hemodialysis-related complications, coagulopathy, and venous thrombosis are likely to hinder the growth of the continuous renal replacement therapy market in the coming years.
North America Expected to Continue to Hold a large Share in the Continuous Renal Replacement Therapy (CRRT) Market
From a geographical outlook, North America holds a major market share of the continuous renal replacement therapy market. This can be primarily attributed to the growing incidences of AKI, technological advancements in continuous renal replacement therapy products, and an increase in the number of diabetic patients in North America.
Some of the key companies operating in the market include Baxter, B. Braun, Fresenius Medical Care AG, Medtronic, and Nipro Corporation, among others.
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market
Companies operating in this market are adopting organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share. Such as,
Â§ In August 2022, Fresenius Medical Care closed a three-way merger including Fresenius Health Partners, the value-based care division of Fresenius Medical Care North America, and created a premier value-based kidney care provider in the U.S
Â§ In April 2022, Baxter International Inc. announced the U.S. FDA 510(k) clearance of the companyâ€™s ST Set used in continuous renal replacement therapy (CRRT)